Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodBreakthrough COVID-19 in Vaccinated Patients with Hematologic Malignancies: Results from the EPICOVIDEHA Survey

In this extensive survey, patients with hematologic malignancies who have breakthrough COVID-19 have approximately 9% reduced mortality rate than they did before vaccination. Patients who received monoclonal antibodies, either alone or in conjunction with antivirals, had superior clinical results.